BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics

Summary

The primary objectives of this study are to investigate * the safety and tolerability of increasing single oral doses of BAY 1830839 versus placebo under fasted conditions * the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted conditions

Timeline

Start

2018-06-28

Primary completion

2019-02-05

Completion

2019-08-01

Drugs

Indications